A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)

Study Summary

This purpose of this study is to establish proof of concept of tebapivat in participants with LR-MDS in Phase 2a and to evaluate the effect of tebapivat on transfusion independence (TI) in participants with LR-MDS in phase 2b.

Conditions

Myelodysplastic Syndromes

Interventions / Drugs

Tebapivat

View on ClinicalTrials.gov ↗

Sponsor

AGIO

Agios Pharmaceuticals

Rare Disease

A86/100

Study Details

Enrollment87 participants

Primary Completion—

Lead SponsorAgios Pharmaceuticals, Inc.

Data Retrieved2026-04-11 02:52:46.814992+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.